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Purpose: Glial cell line-derived neurotrophic factor (GDNF) is neuroprotective of retinal neurons, and transduced retinal
progenitor cells (RPCs) can deliver this cytokine for the treatment of retinal diseases, yet the potential effects of GDNF
on RPCs have received little attention.
Methods: Murine RPCs were assessed under multiple conditions in the presence or absence of epidermal growth factor
(EGF, 20 ng/ml) and/or GDNF (10 ng/ml) using a variety of techniques, including live-cell imaging, caspase-3 activity
assay, whole genome microarray, quantitative polymerase chain reaction (qPCR), and western blotting.
Results: Live monitoring revealed that formation of initial aggregates resulted largely from the collision and adherence
of dissociated RPCs, as opposed to clonal proliferation. Spheres enlarged in size and number, with more reaching the
threshold criteria for cross-sectional areas in the EGF+GDNF condition. Proliferation was measurably augmented in
association with EGF+GDNF, and Ki-67 expression was modestly increased (1.07 fold), as were hairy and enhancer of
split 5 (Hes5), mammalian achaete-scute homolog 1 (Mash1), and Vimentin. However, global gene expression did not
reveal a notable treatment-related response, and the expression of the majority of progenitor and lineage markers examined
remained stable. GDNF reduced RPC apoptosis, compared to complete growth-factor withdrawal, although it could not
by itself sustain mitotic activity.
Conclusions: These data support the feasibility of developing GDNF-transduced RPCs as potential therapeutic agents
for use in retinal diseases.
The neural retina is subject to a range of degenerative
conditions, including those like retinitis pigmentosa and age-
related macular degeneration that involve photoreceptor loss.
Similar to other compartments of the central nervous system,
the  mammalian  retina  lacks  the  capacity  to  regenerate
following  injury,  and  there  are  at  present  no  restorative
therapies available for diseases involving photoreceptor loss.
Retinal progenitor cells (RPCs) actively generate the mature
neurons  and  Müller  glia  of  the  neural  retina  during  eye
development. A large body of evidence has now shown that
RPCs can be isolated, expanded [1-4], and transplanted in
various animal models [1,5-9]. The transplantation of RPCs
to the abnormal retina has become an important strategy in
retinal regeneration research.
Studies on avian and mammalian embryos have identified
factors that influence the behavior of RPCs during normal
retinal  development  and  in  response  to  injury.  Particular
interest has been directed toward the subset of factors with
demonstrated  neuroprotective  efficacy  because  of  their
potential clinical relevance. One important effective molecule
known to rescue retinal neurons, including photoreceptors, in
multiple  animal  models  is  the  glial  cell  line-derived
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neurotrophic  factor  (GDNF)  [10-12].  GDNF  is  a  distant
member of the transforming growth factor-β family of growth
factors  and  a  member  of  the  GDNF  family,  which  also
includes neurturin, persephin, and artemin [13]. GDNF was
originally purified and characterized in 1993 and found to be
a  survival  factor  for  embryonic  dopaminergic  midbrain
neurons in culture [14]. It later became clear that GDNF also
acts  as  a  potent  neurotrophic  factor  in  a  variety  of  other
contexts.  GDNF  is  widely  distributed  in  the  developing
central nervous system and has been confirmed to subserve
pivotal  roles  in  many  additional  tissues,  including  the
peripheral  nervous  system,  inner  ear,  embryonic  kidney,
gastrointestinal  tract,  skeletal  muscle  [15-17]  and
spermatogonial stem cells [18].
In  the  past  few  years,  the  potential  of  GDNF  as  a
therapeutic  agent  for  the  treatment  of  neurodegenerative
conditions such as Parkinson disease, which is characterized
by dopaminergic cell loss, has been actively explored [19,
20]. In the eye, it has been shown that both GDNF and its
receptors  are  synthesized  in  the  retina  [15,21],  thereby
suggesting that this factor has an innate neurotrophic role in
this tissue. Several lines of work, using recombinant protein,
knockout, or overexpression methods, have implicated GDNF
in  the  regulation  of  cell-cycle  progression,  specifically  in
terms of promoting neuroblast proliferation at early stages of
development,  as  well  as  promoting  the  survival  and
differentiation of retinal photoreceptors [22,23]. In addition
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2850to these roles, GDNF may also delay the onset of apoptosis
and  participate  in  the  regulation  of  cellular  migration,
although in this regard the literature is more variable. For
instance, Clarkson and colleagues [24] showed that GDNF
had no discernable effect on apoptosis in astrocytes derived
from  the  embryonic  mesencephalon  or  from  the  neonatal
cortex. Iwashita and colleagues [25] also showed that GDNF
did not affect the survival or proliferation of neural crest stem
cells.  Together,  these  results  indicate  that  although  the
neurotrophic role is well established, the effects of GDNF do
not entirely generalize across cell types or developmental
stages.
GDNF  has  shown  considerable  potential  as  a  novel
therapeutic  agent  for  the  treatment  of  neurodegenerative
diseases, including those of the retina; however, a significant
challenge to implementation has been the need for sustained
local delivery over lengthy time periods. An attractive strategy
for neutrophic factor delivery that has been considered is the
transplantation of stem or progenitor cells that have been
genetically modified to overexpress the particular gene of
interest [26,27]. When contemplating such a strategy, it is
important to consider the impact of the delivered factor on the
behavior of the cell used for delivery. In addition, it is of
interest to know how the factor might influence tissue-specific
stem cells residing within the recipient host tissue. At present,
little is known regarding the influence of GDNF on cultured
RPCs.  Here  we  investigate  the  influence  of  GDNF  on  a
previously  characterized  and  transplantable  population  of
mitotically active progenitor cells derived from the immature
murine retina.
METHODS
Isolation and culture of late retinal progenitor cells: RPCs
were previously isolated from the neural retina of postnatal
day  1GFP  transgenic  mice  [28].  Briefly,  retinas  were
harvested from newborn GFP transgenic C57BL/6 mice (gift
from  Masaru  Okabe,  University  of  Osaka,  Osaka,  Japan)
[29] and subjected to several cycles of collagenase digestion
to dissociate the tissue. Cells were then forced through a nylon
mesh of 100 µm pore size, centrifuged, and resuspended in
standard culture medium, containing Dulbecco’s modified
Eagle’s medium/Ham’s F12 1:1 (Omega Scientific, Tarzana,
CA)  supplemented  containing  1%  (by  vol.)  N2  neural
supplement  (Gibco,  Invitrogen,  Carlsbad,  CA),  2  mM  L-
glutamine (Sigma Aldrich, St. Louis, MO), 2,000 U nystatin
(Gibco), 50 mg/ml penicillin-streptomycin (Sigma), and 20
ng/ml recombinant human epidermal growth factor (EGF;
Invitrogen,  Carlsbad,  CA).  GFP+  neurospheres  appeared
within the first 2 to 3 days. Culture media were changed every
2  days,  and  proliferating  cells  were  passaged  at  regular
intervals of 4–5 days. These cells were immunoreactive for
nestin (a marker for neural progenitor cells) and Ki-67 (a
marker for cell proliferation).
Treatment  conditions:  To  first  determine  the  optimal
concentration of GDNF for use in the present study, we tested
the effects of four different concentrations of GDNF (2.5, 5,
10, and 20 ng/ml) on the gene expression profile of genetically
modified RPCs. Cells were treated with GDNF for 5 days,
RNA was extracted, and a quantitative PCR (qPCR) assay was
performed. The progenitor markers remained at similar levels
to  those  of  untreated  controls  under  the  different
concentrations of GDNF examined (Figure 1). Given this
general equivalence, combined with our interest in looking for
a possible physiologic (as opposed to toxic) influence, we
chose 10 ng/ml for use in our system.
RPCs were cultured in standard base media with the only
difference being the presence or absence of EGF (20 ng/ml)
Figure  1.  Gene    expression  profile 
 of retinal        progenitor     cell    progenitor
markers under different concentrations
of  glial cell line-derived neurotrophic
factor  treatment.  Cultured  genetically
modified  (GFP+)   RPCs  were   treated
with  2.5,  5,  10,  and  20 ng/ml of glial
cell   line-derived   neurotrophic   factor
(GDNF)  for  5   days,  then  RNA  was
isolated,   and  quantitative  polymerase
chain  reaction  (qPCR)  assay  was
performed.  The progenitor markers  in
those   samples   remained   at   similar
levels under different concentrations of
GDNF.  In  each  gene  column,  the  five
bars  from  left to right represent cells in
epidermal  growth  factor  (EGF)  alone
(dark  red),  in  EGF+2.5  ng/ml  GDNF
(dark  green),  in  EGF+5  ng/ml GDNF
(blue),  in  EGF+10  ng/ml GDNF (red),
and in EGF+20 ng/ ml GDNF (green).
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2851and/or  10  ng/ml  recombinant  human  GDNF  (PHC7045;
Biosource, Invitrogen) as follows:
1)  No  recombinant  factors  (nonmitogenic  conditions,
negative control),
2) EGF alone (proliferation conditions, positive control,
i.e., identical to “standard medium”),
3) GDNF alone, or
4) EGF+GDNF together.
All starting total RNA samples were quality assessed
before beginning the target preparation/processing steps by
running out a small amount of each sample (typically 25–250
ng/well) onto a RNA 6000 Nano LabChip that was evaluated
on an Agilent Bioanalyzer 2100 (Agilent Technologies, Palo
Alto, CA). Single-stranded, then double-stranded, cDNA was
synthesized from the poly(A)+mRNA present in the isolated
total RNA (typically 100 ng total RNA starting material for
each  sample  reaction)  using  the  GeneChip  WT  cDNA
Synthesis Kit (Affymetrix, Inc., Santa Clara, CA) and random
hexamers tagged with a T7 promoter sequence. The double-
stranded cDNA was then used as a template to generate many
copies  of  antisense  cRNA  from  an  in  vitro  transcription
reaction for 16 h in the presence of T7 RNA polymerase using
the Affymetrix Genechip WT cDNA Amplification Kit. Ten
micrograms of cRNA were input into the second-cycle cDNA
reaction with random hexamers that were used to reverse-
transcribe the cRNA from the first cycle to produce single-
stranded DNA in the sense orientation.
Morphometry:  Cellular  morphology  was  recorded  on
treatment day 1, 3, and 5 using a microscope-mounted camera
and imaging system. In addition, cellular proliferation and
sphere formation were also recorded and quantified every 45
min  using  an  IncuCyte  live-cell  imaging  system  (Essen
Instruments, Ann Arbor, MI) located within the incubator.
Cell  viability:  RPCs  were  cultured  under  four  different
conditions consisting of the base medium and either no added
growth factors, EGF alone, GDNF alone, or EGF+GDNF, for
5 days. Cell viability was measured using a Cell Counting
Kit-8 assay (Dojindo, Kumamoto, Japan). In brief, cells were
suspended at a final concentration of 1×104 cells/well and
cultured in 96-well, flat-bottomed microplates. At the end of
TABLE 1. PRIMERS USED FOR QUANTITATIVE RT–PCR.
Genes Accession
number
Forward (5′-3′) Reverse (5′-3′) Annealing
temperature
(°C)
Product size
(base pairs)
Nestin NM_016701 aactggcacctcaagatgt tcaagggtattaggcaagggg 60 235
Vimentin NM_011701 tggttgacacccactcaaaa gcttttggggtgtcagttgt 60 269
Sox2 NM_011443 cacaactcggagatcagcaa ctccgggaagcgtgtactta 60 190
Hes1 NM_008235 cccacctctctcttctgacg aggcgcaatccaatatgaac 60 185
Hes5 NM_010419 caccgggggttctatgatatt caggctgagtgctttcctatg 60 180
Pax6 NM_013627 agtgaatgggcggagttatg acttggacgggaactgacac 60 132
Chx10 NM_007701 caatgctgtggcttgcttta cttgagagccactgggctac 60 157
Notch1 NM_008714 acccactctgtctcccacac gcttccttgctaccacaagc 60 123
Mash1 NM_008553 tctcctgggaatggactttg ggttggctgtctggtttgtt 60 142
Ki-67 X82786 cagtactcggaatgcagcaa cagtcttcaggggctctgtc 60 170
β3-tubulin NM_023279 cgagacctactgcatcgaca cattgagctgaccagggaat 60 152
DCX NM_010025 tgtaaactaaaacaaagacccgaag aagtacctcacaagtcaaagaatgg 60 187
Map2 NM_001039934 agaaaatggaagaaggaatgactg acatggatcatctggtaccttttt 60 112
Recoverin NM_009038 atggggaatagcaagagcgg gagtccgggaaaaacttggaata 60 179
Rhodopsin NM_145383 tcaccaccaccctctacaca tgatccaggtgaagaccaca 60 216
PKC-α NM_011101 cccattccagaaggagatga ttcctgtcagcaagcatcac 60 212
CRALBP NM_020599 agggtctttgttcacggagat tgccactagagcgttcctaaa 60 297
GFAP NM_010277 agaaaaccgcatcaccattc tcacatcaccacgtccttgt 60 184
β-actin NM_007393 agccatgtacgtagccatcc ctctcagctgtggtggtgaa 60 152
c-myc NM_010849 gctgtagtaattccagcgagaga aagttccagtgagaagtgtctgc 60 239
Nanog NM_028016 ttggttggtgtcttgctcttt caggaagacccacactcatgt 60 196
SDF1 NM_021704 gtattgtagctttccggtgtcag aggaggtttacagcatgaaacaa 60 120
CXCR4 NM_009911 ctgtgtgatggtttgtttggtt ttctaccaccatttcaggcttt 60 101
Annexin V NM_009673 tgctcaggagtttaagactctgttt taatctcggtcaatactttctcgtc 60 182
Caspase 1 NM_009807 acacgtcttgccctcattatct gcagcaaattctttcacctctt 60 176
Caspase 3 NM_009810 aaggagcagctttgtgtgtgt cgcctctgaagaagctagtca 60 107
P4HB NM_011032 gcagcagaggctattgatgac atcttcggagctgtctgttca 60 221
FSP1 NM_011311 acttccaggagtactgtgtcttcc aaactacaccccaacacttcatct 60 128
KLF4 NM_010637 ctgaacagcagggactgtca gtgtgggtggctgttctttt 60 218
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2852each  treatment  day,  10  μl  WST-8  [2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, monosodium salt] was added to each well. The
plates were incubated for an additional 4 h at 37 °C to convert
WST-8 into formazan. The absorbance was then measured at
450 nm with a spectrophotometer. Cell viability is in direct
proportion to the absorbance at 450 nm; therefore, viability
was  expressed  as  the  A450  value.  All  experiments  were
performed in 96-well plates (ten wells/condition).
Figure 2. Changes in retinal progenitor cell morphology under different culture conditions. Retinal progenitor cell s were cultured in the same
serum-free base media, but under four different treatment conditions defined by the presence or absence of added growth factors, as follows:
1) no growth factor (A-C), 2) glial cell line-derived neurotrophic factor (GDNF) alone (D-F), 3) epidermal growth factor (EGF) alone (G-I),
and 4) EGF+GDNF (J-L). In each case, EGF was used at a final concentration of 20 ng/ml and GDNF at 10 ng/ml. The morphology of cells
in each condition was assessed on day 1, 3, and 5. Increased extension of processes appeared in the “no growth factor” group (A-C; D-F),
with similar changes observed in the “GDNF alone” group (A-C; D-F). Cells grown in EGF+GDNF appeared to form more and larger spherical
cellular aggregates (spheres) over the course of 5 days. Magnification was ×100. Scale bars: 100 μm.
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2853In addition, growth of RPCs in medium with EGF alone,
or with EGF and GDNF, was assessed over a one-month time
course. Cells were passaged before reaching confluence. At
each  passage,  the  cell  number  was  counted  using  a
hemocytometer, and a population doubling level (PDL) was
determined as current PDL=Log(final harvest cell number/
initial seeded cell number)×3.33.
Caspase-3 activity assay: After 24 h culture, RPCs exposed
to  the  four  different  conditions  mentioned  above  were
collected and washed in cold phosphate buffered saline (PBS;
2.68 mM KCI, 1.47 mM KH2PO4, 135.60 mM NaCl, 8.10 mM
Na2HPO4).  Cell  pellets  were  resuspended  in  100  μl  lysis
buffer. After 20 min incubation on ice, each cell lysate was
spun at 18,000× g at 4 °C for 15 min. The supernatant was
collected and 5 μl of cell lysate from each condition was
diluted to 100 μl in the assay buffer consisting of 20 mM
Hepes at pH 7.4, 0.1% CHAPS, 5 mM dithiothreitol, and 2
mM  EDTA,  supplemented  with  2  mM  of  the  caspase-3
substrate  Ac-DEVD-pNA.  The  enzymatic  activity  was
determined  spectrophotometrically  at  405  nm  (molar
absorptivity of p-nitroaniline, εmM=10.5 at 405 nm). Caspase-3
activity was determined as µmol pNA released per minute per
milligram of protein.
RNA  isolation:  RPCs  were  grown  in  culture  media  that
contained EGF or EGF+GDNF for 5 days. Total RNA was
extracted from each sample using the RNeasy Mini Kit (Cat.
No.  74104;  Qiagen,  Valencia,  CA).  After  RNA  isolation,
samples were treated by DNaseI (Macherey-Nagel, Düren,
Germany) to digest and eliminate any contaminating genomic
DNA. RNA concentration was measured for each sample at a
wavelength of 260 nm (A260), and the purity of extracted total
RNA  was  determined  by  the  A260/A280  ratio.  Quantitative
reverse-transcriptase PCR analyses and microarray analysis
were only performed on samples with A260/A280 ratios between
1.9 and 2.1.
Microarray processing and analysis: After RNA isolation
(two treatments, with three samples per treatment), 1 μg total
RNA from each sample was used to prepare material for
hybridization with each of the six Affymetrix mouse gene 1.0
ST arrays at the UCI Genomics High-Throughput Facility at
the University of California, Irvine, as recommended by the
manufacturer (Affymetrix Genechip Whole Transcript Sense
Target Labeling Assay Manual; Affymetrix, Inc., Santa Clara,
CA).  The  integrity  and  concentration  of  total  RNA  were
measured,  followed  by  hybridization,  scanning,  and
generation of raw expression data, which were subsequently
normalized using a standard technique by the same facility, as
follows.
The single-stranded DNA sample was fragmented (WT
Terminal  Labeling  Kit,  Affymetrix)  to  an  average  strand
length of 60 bases (range 40–70 bp) following prescribed
protocols (Affymetrix GeneChip WT Sense Target Labeling
Assay Manual). The fragmented single-stranded DNA was
subsequently  labeled  with  recombinant  terminal
deoxynucleotidyl transferase and the Affymetrix proprietary
DNA Labeling Reagent, which is covalently linked to biotin.
Figure  3.  Still  frames  taken  at  the
following time points in culture: A. Day
0, 3:45 h; B. Day 1, 11:15 h; C. Day 3,
17:03  h;  D.  Day  5,  14:03  h.  These
images highlight the basic findings of
the time-lapse experiment, namely, the
simultaneous  enlargement  of  focal
aggregates  (proto-spheres)  together
with  the  progressive  decrease  in  the
overall number of aggregation centers.
In the video this can be seen to largely
correspond to the adherence of cells and
cellular clusters over time.
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2854Following  the  recommended  procedure,  0.54  μg  of  this
fragmented single-stranded target cDNA was hybridized at
45  °C  with  rotation  for  17  h  (Affymetrix  GeneChip
Hybridization  Oven  640)  to  probe  sets  present  on  an
Affymetrix mouse-gene 1.0 ST array. The GeneChip arrays
were washed and then stained (streptavidin-phycoerythrin) on
an  Affymetrix  Fluidics  Station  450  (Fluidics  protocol
FS450_007).  Arrays  were  scanned  using  the  GeneChip
Scanner 3000 7G and GeneChip Operating Software v1.4 to
produce CEL intensity files.
Normalization  was  performed  using  the  probe
logarithmic intensity error (PLIER) estimation method, which
includes  a  quantile  normalization  protocol  within  the
associated software algorithm. Briefly, the probe cell intensity
files  (*.CEL)  generated  above  were  analyzed  using
Affymetrix  Expression  Console  software  v1.1  using  the
PLIER algorithm to generate probe-level summarization files
(*.CHP).  The  algorithm  used  was  from  PLIER  v2.0
(quantification scale: linear; quantification type: signal and
detection  p  value;  background:  PM-GCBG;  normalization
method: sketch-quantile).
Statistical  analysis  was  subsequently  conducted  using
JMP Genomic 3 software (SAS Institute Inc.) The raw data
were log-2 transformed and imported into the software for
analysis.  The  strategy  used  was  to  compare  the  gene
expression profile of the control group (EGF alone) with the
experimental group (EGF+GDNF). Data from the arrays were
analyzed by the clustering of differences between treatments
and  identification  of  significant  changes.  Changes  were
considered  statistically  significant  if  the  difference  in
expression between the groups had a p value less than 0.05.
Figure 4. Quantitative analysis of sphere formation under different culture conditions. The left panel shows phase (A) and fluorescent (B)
photomicrographs of murine retinal progenitor cells (RPCs). Examples of object thresholding and quantification using image analysis software
are shown (C-F), with white indicating selected objects and red indicating rejected objects. Specifically, a given microscopic field is
thresholded to select all spheres (C), small spheres (D), middle-sized spheres (E), and large spheres (F; none present in this image). The scale
bar is 400 µm. Right panel: RPCs were cultured in medium containing epidermal growth factor (EGF) or EGF + glial cell line-derived
neurotrophic factor (GDNF) for 5 days. Number and cross-sectional area of spherical cellular aggregates (spheres) larger than 870 µm2 are
shown for each time point. Spheres meeting threshold criteria increased in number along the time course in both conditions. Significantly
greater numbers and larger area of the spheres were found in the EGF+GDNF condition, compared to EGF at day 5, with the earlier trend
seen at day 1 and day 3 not reaching statistical significance by the criterion used. Data represent the mean of six samples from same plating
(*p<0.05). x-axis shows different medium conditions at day 1, 3, and 5; y-axis shows the number of spheres. Different shading within the
histogram shows sphere area (µm2). Black is for small spheres, light gray for middle-sized, and dark gray for large. Standard deviation was
used to generate the error bars, which reflect the sphere numbers.
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2855Reverse transcription and quantitative PCR: To further assess
expression  changes,  transcription  levels  of  selected  genes
were  examined  by  performing  semiquantitative  real-time
PCR using an Applied Biosystems 7500 Fast Real-Time PCR
Detection System (Applied Biosystems, Foster, CA). Two
micrograms of total RNA in a 20 μl reaction volume were
reverse-transcribed using an Omniscript cDNA Synthesis Kit
(Qiagen). Oligonucleotide primer sequences (Table 1) were
designed  using  Primer  3  software.  The  primers  were
synthesized  commercially  (Invitrogen)  and  qPCR  was
performed in 20 μl total volume containing 10 μl of 2× Power
SYBR Green PCR Master Mix (Applied Biosystems), 10 μl
of  cDNA,  and  300  nM  of  gene-specific  primers.  Cycling
parameters for qPCR were as follows: initial denaturation at
95 °C for 10 min, followed by 40 cycles of 15 s at 95 °C and
of 1 min at 60 °C. To normalize template input, the β-actin
transcript level was measured for each sample (endogenous
control). The efficiency of the PCR reaction was measured
with primers using serial dilution of cDNA (1:1, 1:5, 1:25,
1:125, 1:625, and 1:3,125). The relative expression of the gene
of interest, (Etarget) ΔCt target (control-treated)/(Eref)ΔCt ref
(control-treated) [30], was then evaluated by the Pfaffl method
[30]. The value obtained for crossing threshold (Ct) represents
the number of PCR cycles at which an increase in fluorescence
signal  (and  therefore  cDNA)  can  be  detected  above  the
background. The increase is exponential for the particular
gene. Data are expressed as fold-change relative to untreated
controls, after normalizing to β-actin (our choice from among
a set of “house-keeping” genes).
Western  blotting:  Samples  for  protein  analyses  were
homogenized in CelLytic M (C2978; Sigma), and proteins
were  measured  using  the  Bio-Rad  detergent-compatible
protein assay (500–0006; Bio-Rad). Proteins (50 µg) were
electrophorised  using  a  3%–8%  Tris-acetate  gel
(EA0375BOX; Invitrogen) for 70 min at 150 V and then
transferred from the gel to a polyvinyldifluoride membrane
using  an  iBot  Gel  Transfer  Device  (IB1001;  Invitrogen).
Western  blotting  was  then  performed  using  the
WesternBreeze Chromogenic Western Blot Immunodetection
Kit (WB7103, Invitrogen) according to the manufacturer’s
protocol. After blockade of nonspecific binding sites using
Blocker/Diluent  solutions  provided,  the  polyvinylfluoride
membranes were incubated for 2 h at room temperature with
mouse  primary  antibodies  directed  against  either  Ki-67
Figure  5.  Viability  of  murine  retinal
progenitor  cells  (RPCs)  in  different
culture  media.  A:  Murine  RPCs
exhibited  exponential  growth  in  the
presence  of  epidermal  growth  factor
(EGF) alone (20 ng/ml), as well as with
EGF+Glial  cell  line-derived
neurotrophic factor (GDNF; 20 and 10
ng/ml,  respectively),  but  diminished
from  day  1  in  the  absence  of  both
factors,  or  with  GDNF  alone.  A
difference in the surviving cell number
between  the  EGF-containing  groups
was  observed,  with  the  addition  of
GDNF  to  the  medium  conferring  a
statistically significant advantage over
EGF alone at day 5. This effect was not
evident at earlier time points. The y-axis
shows  absorbance  at  450  nm.  All
experiments were performed in 96-well
plates (ten wells/condition). Error bars
show  standard  deviation  (SD),  *
indicates p<0.03. B: Growth of RPCs
over a one-month period in EGF or EGF
+GDNF was monitored by manual cell
counts  (with  a  hemocytometer).  The
growth curves thus obtained confirmed
that the addition of GDNF (10 ng/ml) to
standard EGF-containing medium does
not impair the proliferation of murine
RPCs and in fact provides a detectible
advantage.
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2856(556003, 1:200; BD), nestin (611658, 1:200; BD), or β-actin
(A5441, 1:200; Sigma). This was followed by washing and 1
h  incubation  with  an  alkaline  phosphatase-conjugated
antimouse  IgG  secondary  antibody  provided  in  the  kit.
Immunoblots were developed using chromogenic substrate
for 10 min. The reactive bands were scanned and quantified
by densitometry using UN-SCAN-IT Gel 6.1 (Silk Scientific,
Inc.  Orem,  UT)  The  density  of  product  from  the  EGF
treatment group was defined as 1, and the data from the EGF
+GDNF condition was expressed as the fold-change of this
value.
Statistical analysis: The results represent the average of three
experiments (±SE). Except where specifically indicated, each
experiment was performed in triplicate. For cell viability and
caspase-3 activity studies, ten fields per sample were analyzed
for each condition. Statistical significance was determined by
Student’s two-tailed t-test.
RESULTS
RPC morphology and sphere formation: RPCs were subjected
to different treatment conditions for up to 5 days. As a result,
Figure 6. Change in caspase-3 activity. Cells were compared in terms
of  caspase  activity  under  the  same  treatment  conditions  used
previously, i.e., no growth factor, glial cell line-derived neurotrophic
factor (GDNF), epidermal growth factor (EGF) and EGF+GDNF for
24 h. Experiments were performed in triplicate. Caspase-3 activity
was  evaluated  spectrophotometrically  at  405  nm  in  whole-cell
lysates  and  calculated  by  construction  of  a  para-nitroaniline
calibration curve (data not shown). The y-axis represents percentages
of caspase-3 activity related to EGF medium (control; n=10). Data
are expressed as the mean±SD (p>0.05 versus EGF; p<0.05 versus
EGF; p<0.05 versus no growth factor).
the morphology of RPCs clearly differed in response to the
presence or absence of EGF (Figure 2). There was increased
extension of processes in response to the absence of EGF
(Figure 2A-F), whereas the appearance of undifferentiated
RPCs cultured in either EGF alone or EGF+GDNF remained
stable  throughout  the  treatment  period.  Undifferentiated
RPCs either adhered to the surface of the uncoated flasks or
were observed floating in the culture medium, either as single
cells or spheres of different sizes. From day 3, short processes
with few, if any, branches extended from some of the adherent
cells (Figure 2H,K). No obvious morphological differences
were observed in response to the presence of 10 ng/ml GDNF
(GDNF alone) when compared to culture conditions without
EGF (no recombinant factors; Figure 2D-F). However, in the
presence of GDNF (EGF+GDNF), more and larger spheres
were observed, as compared to EGF alone (Figure 2I,L).
The proliferation of RPCs and formation of spherical
cellular  aggregates  (spheres)  were  also  monitored  via  the
IncuCyte  system  over  the  five-day  time  course,  allowing
comparison of EGF and EGF+GDNF conditions. By way of
the acquired video, dissociated RPCs were seen to exhibit a
strong propensity to aggregate in culture, with the formation
of  spheres  being  evident  as  early  as  5.5  h  after  seeding.
Aggregates started with the movement of suspended single
RPCs within the culture medium and adherence to other cells,
as  opposed  to  cell  division  and  clonal  expansion  (see
Appendix 1, Figure 3). Over time, the spheres enlarged and
their  movement  lessened,  consistent  with  an  increased
contribution of cell proliferation to sphere formation. The
number of spheres with a cross-sectional area of >870 µm2
increased in both treatment conditions, beginning on day 0
and continuing to day 5, at which time greater numbers of
spheres  had  reached  threshold  criteria  in  the  GDNF-
supplemented medium (p<0.05). In addition, more spheres
had attained higher categories of cross-sectional area in this
treatment condition as well, consistent with increased cellular
proliferation (Figure 4).
Cell  viability  and  proliferation:  Murine  RPCs  exhibited
exponential growth in the presence of EGF alone, as well as
with  EGF+GDNF,  but  diminished  asymptotically  in  the
absence of both factors, or with GDNF alone. Cell viability
was compared for the EGF alone versus the EGF+GDNF
conditions using the cell-counting kit. By this method, the
number of RPCs increased from day 1 to 4, although there was
no difference between conditions. By day 5, however, there
were  significantly  more  viable  cells  in  the  EGF+GDNF
compared to those in EGF alone (Figure 5A). Moreover, the
growth over a one-month period confirmed that the addition
of GDNF to a standard EGF-containing proliferation medium
provides sustained augmentation of RPC numbers (Figure
5B).
Caspase-3 activity: We determined the level of caspase-3
activity under conditions with or without EGF or GDNF after
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285924  h  treatment.  Caspase-3  activity  levels  with  no  growth
factors,  as  well  as  with  GDNF  alone,  were  substantially
elevated compared to conditions that included EGF (p<0.05),
and activity was significantly higher in the no-growth-factor
condition than in GDNF alone (p<0.05). Between EGF and
EGF+GDNF, no difference was observed (Figure 6).
Microarray screening for GDNF-induced changes in gene
expression: The signal levels of individual cDNA from the
experimental (EGF+GDNF) and control (EGF) groups were
compared  after  hybridization  on  a  mouse  whole-genome,
gene-level microarray that consisted of over 28,853 genes.
The  fold  change  and  p  value  of  each  of  the  genes  were
calculated, and log2 (fold change) and −log10 (p value) were
transformed. Genes with a p value of <0.05 and an absolute
fold  change  value  of  >1  were  arbitrarily  defined  as
upregulated in GDNF-treated cells, whereas those with a p
value <0.05 and an absolute fold change value of <1 were
defined as downregulated. The distribution analysis was done
as  a  quality  control  step.  The  overlayed  kernel  density
estimates (Figure 7A) derived from the distribution analysis
showed the raw univariate distributions for all arrays, and
allowed the visualization of sources of variation attributed to
technical procedures. The distributions for these arrays were
very similar, indicating that this represented a high-quality
data  set  requiring  little  if  any  normalization  for  further
analysis.  Principle  component  analysis  revealed  a  broad
degree of overlap in expression patterns between the two
treatment  conditions,  with  little  suggestion  of  a  treatment
effect (Figure 7C). However, ANOVA analysis showed that
of the approximately 25,189 genes that were expressed in the
cultures  treated  with  EGF+GDNF,  5,250  of  these  were
associated with the presence of GDNF (Figure 7B). A total of
3,865  genes  were  upregulated  and  1,385  genes  down
regulated following the addition of GDNF to EGF-containing
standard medium. In this case, changes in 24 genes were
detected in the EGF+GDNF condition (Table 2). Among those
were 16 known and eight predicted genes, the latter not yet
associated with any biologic functions (data not shown). Of
the 16 known genes, six were olfactory receptors with three
being upregulated and three down-regulated. There were two
genes  with  possible  associations  to  photoreceptor  cilia,
namely  myosin  IXa  and  a  dynein  (Dnahc7a);  however,
changes were slight and in opposite directions.
Effect  of  GDNF  on  RPC  gene  expression  determined  by
qPCR:  In  addition  to  checking  for  global  changes,  the
potential influence of GDNF on a specific subset of genes with
known  associations  to  RPCs  was  also  evaluated  using
quantitative PCR. Following treatment of RPCs with GDNF
for up to 5 days, expression of most progenitor-associated
markers remained effectively stable (Figure 8). At baseline,
in  the  presence  of  EGF,  cultured  RPCs  expressed  the
progenitor  markers  Nestin,  Ki-67,  ceh-10  homeo  domain
containing homolog (C. elegans) [Chx10], sex determining
region  Y-box  2  (Sox2),  v-myc  myelocytomatosis  viral
oncogene  homolog  (avian)  [C-myc],  and  Vimentin.  This
pattern was sustained in the EGF+GDNF condition. Similarly,
the expression levels of precursor and lineage-related markers
including  βIII-tubulin,  microtubule-associated  protein  2
(MAP2), doublecortin (DCX), cellular retinaldehyde binding
protein  (CRALBP),  protein  kinase  C,  alpha  (PKC-α),  and
Recoverin. These were relatively unaffected by the addition
of GDNF to the EGF-based proliferation medium (Figure 1).
Of the above markers, a subset exhibited marginally increased
expression, namely, Hes5 (1.03-fold), Ki-67 (1.07-fold), Mash
1 (1.12-fold) and Vimentin (1.20-fold; Figure 8). Of these, the
microarrays  showed  no  significant  difference  for  Hes5,
Ki-67, or Vimentin (Mash 1 was not included; Table 3). Taking
the comparison further, the qPCR data did not confirm the
marginal  changes  seen  with  the  microarrays  for  Nanog,
Notch1, or GFAP.
Western  blot  analysis:  PCR  detects  changes  in  mRNA
expression; however, the extent to which these changes are
reflected at the level of proteins is also of interest. Western
blotting was employed for this purpose on samples from the
EGF alone and the EGF+GDNF treatment groups. Nestin was
used as a marker of neural progenitor cells and Ki-67 as a
marker of cell proliferation.
Anti-nestin  identified  two  bands  with  the  anticipated
molecular weight, approximately 220 kDa and 200 kDa, with
β-actin labeling used as the loading control. The upper band
of nestin (approximately 220 kDa) was strongly labeled in
both the EGF and EGF+GDNF conditions and the lower band
(approximately  200  kDa)  was  little  changed  in  the  EGF
+GDNF condition, compared with EGF alone. Overall, no
significant  difference  between  treatment  conditions  was
detected by quantification of the entire blot-lane intensity.
Two bands were detected by Ki-67 antibody, approximately
395 kDa and 345 kDa. Quantification analysis showed that
the intensity of the entire blot lane was increased in the EGF
+GDNF condition by 1.189±0.0095-fold (Figure 9). These
results at the protein level were consistent with the mRNA
results for Nestin and Ki-67, as determined by qPCR (Figure
8), namely, that the total Nestin mRNA did not change in
response  to  EGF+GDNF  treatment  over  5  days,  whereas
Ki-67 was slightly upregulated (Figure 9).
DISCUSSION
Cytokines and stem cells are both powerful biologic agents
and feature in many regenerative strategies currently being
investigated.  While  these  two  categories  of  agents  have
evident therapeutic potential in their own right, the possibility
that complementary or synergistic effects could be achieved
using a combinatorial approach is also worthy of attention. Of
particular interest in the setting of retinal degeneration is the
use of tissue-specific progenitors, namely RPCs, to deliver
neurotrophic factors with known neuroprotective activity, a
notable example being GDNF. It has been established that
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2860Figure 7. Overlayed kernel density estimates, principle component analysis, and volcano plot. A: Overlayed kernel density estimates show
the raw univariate distributions for all arrays. The distributions for these arrays are very similar, indicating that this is a high-quality data set
that should require little if any normalization for further analysis. B: Volcano plot from ANOVA analysis of the differential expression under
epidermal growth factor (EGF) and EGF+glial cell line-derived neurotrophic factor (GDNF) conditions reveals differentially expressed genes.
The fold change values between two conditions (log10 transformed) were plotted on the x-axis and were compared to the negative log10
transformed p values on the y-axis. Genes with a transformed p value of at least 0.05 and a transformed fold change of at least two in the upper
left and upper right of the volcano plot are highlighted in red. Among these genes, eight are predicted genes and the other 16 are listed in Table
2. Histograms along the borders were generated via all detected genes. The dotted straight horizontal line represents the value 1.3 [-log10 (p
value=0.05)], and the genes above that line are significantly different in expression level between the two conditions. The pale green bars in
the histograms along the borders show numbers of all genes, and the dark green bars inside represent genes with a p value of <0.05. C: Principle
component analysis (PCA) of gene expression signals reveals a broad degree of overlap in expression patterns between the two treatment
conditions, with little suggestion of a treatment effect. Blue indicates data from retinal progenitor cells (RPCs) cultured in standard, epidermal
growth factor-based medium (SM), while red indicates data from standard medium supplemented with GDNF. Individual microarrays (3 each
condition) are indicated as small orbs and the general data distribution for each condition as an elliptical field of the corresponding color.
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2861cultured  central  nervous  system  progenitor  cells  can  be
transduced  to  express  a  variety  of  transgenes  [31-33],
including GDNF [27,34]. Because the role of GDNF can differ
between cell types and developmental stages, it is important
to understand the effect of this factor not only on the retina,
but also on potential donor cells such as RPCs. Here, we have
shown  that  exogenous  GDNF  has  several  subtle  yet
discernable influences on cultured murine RPCs, including
augmentation  of  EGF-induced  proliferation  as  well  as  a
modest reduction in apoptosis when EGF is withdrawn.
A growing body of work has shown that growth factors,
alone or in combination, exert important effects on cellular
behavior,  particularly  during  development.  For  example,
Zheng and colleagues [35] have shown that EGF, fibroblast
growth  factor,  and  hepatocyte  growth  factor  all  induce
changes in fetal liver hepatocytes in vitro, and that different
combinations of these growth factors show various effects on
the proliferation and differentiation of the cells. Salient to the
current report, Ahmad and colleagues have shown that retinal
progenitors proliferate and remain undifferentiated in vitro in
the presence of epidermal growth factor (EGF), and display
properties similar to stem cells [36], as have we, having tested
the same murine RPCs here [3]. Ahmad and colleagues [37]
have also shown that EGF can mediate suppression of retinal
rod photoreceptor differentiation. Although the influence of
EGF and ciliary neurotrophic factor (CNTF) on RPCs has
been  reported,  the  influence  of  GDNF  has  not,  to  our
knowledge, been previously investigated. The relative lack of
response of murine RPCs to GDNF found in the present study
is in contrast to what we have previously shown for other
treatment conditions, namely serum as well as a different
cytokine, CNTF [38]. Both serum and CNTF had notable
differentiating  influences  on  murine  RPCs,  whereas  the
present  study  indicates  that  GDNF  does  not,  under
comparable conditions. In the presence of EGF, exposure to
GDNF  appears  to  be  compatible  with  maintaining  the
undifferentiated state of these cells.
GDNF has emerged as a particularly important cytokine
by  virtue  of  its  powerful  neuroprotective  influence,  as
demonstrated in multiple models of neurodegeneration [39,
40].  However,  despite  significant  progress  in  the
understanding of the GDNF signaling pathways and receptor
interactions, the exact cellular mechanisms responsible for
these neuroprotective effects are not yet fully understood.
Furthermore,  despite  therapeutic  promise  in  the  clinical
treatment of retinal and other diseases, this growth factor has
yet  to  be  validated  in  the  treatment  of  patients.  A  major
challenge to the use of cytokines is their rapid breakdown in
vivo by endogenous proteases. Cell-based delivery of these
molecules is attractive for this reason, and the present findings
have  implications  for  the  development  of  GDNF-
overexpressing RPCs.
In terms of the effects reported in the present study, a
proliferative influence has been described previously, and it
has been reported that GDNF is able to improve the survival
and differentiation, both in vivo and in vitro, of a variety of
brain  neurons  [41,42],  as  well  as  being  essential  for  the
proliferation of enteric precursor cells [43]. Similarly, GDNF
Figure 8. Effect of the glial cell line-derived neurotrophic factor (GDNF) on gene expression profile of retinal progenitor cell (RPCs) evaluated
by qPCR. After 5 days of culturing in either the epidermal growth factor (EGF) alone or in EGF+GDNF conditions, the expression of the
selected progenitor through retinal and apoptosis markers was evaluated by quantitative reverse-transcription PCR. For each gene, expression
levels in the EGF-alone condition (black) were set to 1.0, and the relative expression in the EGF+GDNF condition (gray) was expressed
proportionately. Expression levels of the progenitor markers Nestin, Sox2, Ki-67, Chx10, C-myc, and Vimentin were sustained with the addition
of GDNF, suggesting that the progenitor phenotype is not negated by exposure to this cytokine. Similarly, expression levels of the precursor
and lineage-related markers CRALBP, PKC-α, βIII-Tubulin, MAP2, DCX, and Recoverin were not significantly affected by the addition of
GDNF to EGF-based proliferation medium. However, there were small but statistically significant increases in the expression of Vimentin
(1.20 fold), Mash 1 (1.12 fold), Ki-67 (1.07 fold), and Hes5 (1.03 fold) versus the same gene under EGF-alone conditions (*p<0.05). The x-
axis shows different genes; the y-axis shows ratios of mRNA expression levels for the treatment groups.
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2862has  been  found  to  stimulate  proliferation  during  renal
development [44]. Beyond this, a regulatory mitogenic effect
has  been  demonstrated  for  rat  glioma  cells  by  adding
exogenous GDNF or using antisense oligonucleotides for the
suppression  of  endogenous  GDNF.  Moreover,  a  similar
proliferative  effect  of  GDNF  has  been  established  in
photoreceptor-enriched  rat  monolayer  cultures  [45].  Our
current data extend these findings to the in vitro behavior of
RPCs, a cell type of great developmental significance in the
retina.  It  remains  possible  that  different,  and  potentially
deleterious, effects could be produced by exposure of RPCs
to  GDNF  at  substantially  higher  concentrations,  as  might
occur  with  very  high  overexpression  of  an  otherwise
therapeutic transgene.
Figure 9. Western blot analysis of retinal progenitor cell (RPCs)
cultured with either epidermal growth factor (EGF) or EGF+GDNF
for 5 days. A: Anti-nestin identified two distinct protein bands with
anticipated  molecular  weights  of  approximately  220  kDa  and
approximately 200 kDa. Two bands were also identified by anti-
Ki-67  with  molecular  weights  approximately  395  kDa  and
approximately 345 kDa consistent with the molecular weights of
alternatively spliced Ki-67 isoforms [31]. Lane a: nestin in EGF; lane
b: nestin in EGF+GDNF; lane c: Ki-67 in EGF; lane d: Ki-67 in EGF
+GDNF. β-actin was used as the loading control (lower panels). B:
Quantitative  analysis  showed  no  significant  difference  in  nestin
expression between treatment conditions. For Ki-67, there was a
statistically significant increase in total protein expression for the
EGF+GDNF condition of 1.18±0.009 fold (*p<0.02).
Of  importance  to  the  development  of  GDNF-
overexpressing RPCs, neither augmentation of proliferation
nor  reduction  in  apoptosis  pose  an  impediment  to  the
expansion of these cells in culture. This allays one potential
concern  that  arises  when  contemplating  the  genetic
modification of a proliferative cell type for cytokine delivery.
In other words, it is important that a constitutively expressed
therapeutic transgene not impede the proliferative ability of
the carrier cell, thereby necessitating repeated re-derivation
and  genetic  modification.  For  instance,  CNTF  has
demonstrated potential as a neurotrophic agent, however, the
known differentiating influence of this factor on RPCs could
pose a hindrance to the use of this candidate transgene. It is
also  important  that  the  potential  therapeutic  molecule  not
induce undesirable changes in the phenotypic status of the cell
used for delivery. In this context, it is reassuring that the global
gene expression of murine RPCs was not substantially altered
by exposure to GDNF.
Conclusions: This study shows that GDNF is not a potent
inducer of RPC differentiation. Its results support the use of
these cells for GDNF delivery to the diseased retina. Because
the  expression  profile  of  cultured  RPCs  is  not  markedly
altered  by  exposure  to  GDNF,  it  may  be  the  case  that
transduced RPCs will retain their ability to repopulate local
retinal populations following transplantation.
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2865Appendix  1:  Time-lapse  video  record  of  cultured  transduced  retinal
progenitor cells.
Appendix 1 sequence of genetically modified transduced
retinal progenitor cells cultured with EGF+GDNF for 5 days.
Data shown were captured in the incubator by the Incucyte
Live Cell Monitoring System (Essen BioScience, Ann Arbor,
MI). Attention to cell motion and cluster formation reveals
that contact and adherence between dissociated cells plays a
prominent role in the initial stages of sphere formation. The
time counter is shown in the inset.
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